Drugs for psychosis can cause weight gain and metabolic disorders in schizophrenia. Given its partial agonistic activity at histamine receptors, betahistine could shape the effects of drugs for psychosis on weight gain and food intake. This study evaluates the effect of betahistine administration on anthropometric indices and symptoms of schizophrenia in schizophrenic patients.
Methods:
This randomized controlled trial was conducted on schizophrenic patients between 2020 and 2022. After stratification based on the type of treatment (olanzapine (n = 28) or risperidone (n = 28)), patients of each stratum were randomly divided into two groups (betahistine or placebo). The duration of the intervention was 12 weeks. Betahistine was started at 8 mg/day and gradually increased to 48 mg in 11 days. Anthropometric indices were measured monthly, while fasting blood glucose, lipid profile, TSH, and Positive and Negative Syndrome Scale (PANSS) were assessed at baseline and 12 weeks.
Results:
All anthropometric measures improved in patients receiving betahistine, except for increased waist circumference in those receiving olanzapine + betahistine. Triglyceride levels were significantly reduced in the olanzapine + betahistine subgroup compared to the placebo group (−12.14 ± 15.49 vs −0.28 ± 9.31; p = 0.021). Moreover, PANSS decreased significantly in all groups during the study, but the difference between groups was not significant.
Conclusion:
The addition of betahistine appears to be well tolerated and positively influences anthropometric indices. These findings suggest that betahistine may help mitigate some of the metabolic side effects of drugs for psychosis, although further research is needed to confirm these effects and to explore the optimal dosage.
Trial registration number:
IRCT20191223045870N1 in Iranian Registry of Clinical Trials (https://irct.behdasht.gov.ir/).
BaiLLiangWWangY, et al. (2023) Effects of adjunctive betahistine therapy on lipid metabolism in patients with chronic schizophrenia: A randomized double-blind placebo-controlled study. Neuropsychiatr Dis Treat19: 453–460.
2.
BakMFransenAJanssenJ, et al. (2014) Almost all antipsychotics result in weight gain: A meta-analysis. PLoS One9: e94112.
3.
BallonJSPajvaniUFreybergZ, et al. (2014) Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol Metab25: 593–600.
4.
BarakNBeckYAlbeckJH (2016a) Betahistine decreases olanzapine-induced weight gain and somnolence in humans. J Psychopharmacol30: 237–241.
5.
BarakNBeckYAlbeckJH (2016b) A randomized, double-blind, placebo-controlled pilot study of betahistine to counteract olanzapine-associated weight gain. J Clin Psychopharmacol36: 253–256.
6.
BuhagiarKJabbarF (2019) Association of first-vs second-generation antipsychotics with lipid abnormalities in individuals with severe mental illness: A systematic review and meta-analysis. Clin Drug Investig39: 253–273.
7.
ChangSCGohKKLuML (2021) Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: State-of-the-art and future perspectives. World J Psychiatry11: 696–710.
8.
CorrellCUSchoolerNR (2020) Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat16: 519–534.
9.
DayabandaraMHanwellaRRatnatungaS, et al. (2017) Antipsychotic-associated weight gain: Management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat13: 2231–2241.
10.
De BerardisDRapiniGOlivieriL, et al. (2018) Safety of antipsychotics for the treatment of schizophrenia: A focus on the adverse effects of clozapine. Ther Adv Drug Saf9: 237–256.
11.
de SilvaVASuraweeraCRatnatungaSS, et al. (2016) Metformin in prevention and treatment of antipsychotic induced weight gain: A systematic review and meta-analysis. BMC Psychiatry16: 341.
12.
DengCWeston-GreenKHuangXF (2010) The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain?Prog Neuropsychopharmacol Biol Psychiatry34: 1–4.
13.
EllulPDelormeRCorteseS (2018) Metformin for weight gain associated with second-generation antipsychotics in children and adolescents: A systematic review and meta-analysis. CNS Drugs32: 1103–1112.
14.
ElnaemMH (2022) Efficacy and safety of second-generation antipsychotics in schizophrenia pharmacotherapy: A comparative narrative. Malays J Med Health Sci18: 183–190.
15.
FitzgeraldIO’DwyerSBrooksM, et al. (2021) Worth the weight? Olanzapine prescribing in schizophrenia. A review of weight gain and other cardiometabolic side effects of olanzapine. Front Psychiatry12: 730769.
16.
GBD Mental Disorders Collaborators (2022) Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry9: 137–150.
17.
HakamiAYFelembanRAhmadRG, et al. (2022) The association between antipsychotics and weight gain and the potential role of metformin concomitant use: A retrospective cohort study. Front Psychiatry13: 1100.
18.
HuhnMNikolakopoulouASchneider-ThomaJ, et al. (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Lancet394: 939–951.
19.
IqbalMMSwatiSAnejaA, et al. (2016) Most common side effects of clozapine and their management. Int J Emerg Ment Health18: 1–6.
20.
KangDJingZLiR, et al. (2018) Effect of Betahistine and Metformin on antipsychotic-induced weight gain: An analysis of two clinical trials. Front Psychiatr9: 620.
21.
KhokharJYHenricksAMSullivanEDK, et al. (2018) Chapter seven – unique effects of clozapine: A pharmacological perspective. In: PasternakGWCoyleJT (eds.) Advances in Pharmacology. Cambridge, MA: Academic Press, pp. 137–162.
22.
KoY-HJoeS-HJungI-K, et al. (2005) Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol28: 169–175.
23.
LangXLiuQFangH, et al. (2021) The prevalence and clinical correlates of metabolic syndrome and cardiometabolic alterations in 430 drug-naive patients in their first episode of schizophrenia. Psychopharmacology238: 3643–3652.
24.
LianJHuangX-FPaiN, et al. (2014) Preventing olanzapine-induced weight gain using betahistine: A study in a rat model with chronic olanzapine treatment. PLoS One9: e104160.
25.
LianJHuangXFPaiN, et al. (2016) Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications. Pharmacol Res106: 51–63.
26.
LisMStańczykiewiczBLiśkiewiczP, et al. (2020) Impaired hormonal regulation of appetite in schizophrenia: A narrative review dissecting intrinsic mechanisms and the effects of antipsychotics. Psychoneuroendocrinology119: 104744.
27.
LiuX (2022) The treatment of schizophrenia. Highlights Sci Eng Technol8: 250–255.
28.
MazhariSKaramoozAShahrbabakiME, et al. (2021) Validity and reliability of a Persian version of the self-evaluation of negative symptoms (SNS). BMC Psychiatry21: 1–5.
29.
MitchellAJVancampfortDSweersK, et al. (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—A systematic review and meta-analysis. Schizophr Bull39: 306–318.
30.
MosolovSNYaltonskayaPA (2022) Primary and secondary negative symptoms in schizophrenia. Front Psychiatry12: 766692.
31.
NielsenMRostrupEWulffS, et al. (2016) Striatal reward activity and antipsychotic-associated weight change in patients with schizophrenia undergoing initial treatment. JAMA Psychiatry73: 121–128.
32.
OkuyamaYKazutoOShinjiM, et al. (2016) Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: A systematic review and meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat12: 3221–3236.
33.
PillingerTBeckKGobjilaC, et al. (2017) Impaired glucose homeostasis in first-episode schizophrenia: A systematic review and meta-analysis. JAMA Psychiatry74: 261–269.
34.
PillingerTMcCutcheonRAVanoL, et al. (2020) Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. Lancet Psychiatry7: 64–77.
35.
PoyurovskyMFuchsCPashinianA, et al. (2013) Reducing antipsychotic-induced weight gain in schizophrenia: A double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology (Berl)226: 615–622.
36.
SmithRCMaayanLWuR, et al. (2018) Betahistine effects on weight-related measures in patients treated with antipsychotic medications: A double-blind placebo-controlled study. Psychopharmacology235: 3545–3558.
37.
SolmiMSeitidisGMavridisD, et al. (2023) Incidence, prevalence, and global burden of schizophrenia – data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Mol Psychiatry28: 5319–5327.
38.
TandonRGaebelWBarchDM, et al. (2013) Definition and description of schizophrenia in the DSM-5. Schizophr Res150: 3–10.
39.
WahidZAliS (1999) Side effects of olanzapine. Am J Psychiatry156: 800a–801.
40.
WangCShiWXuJ, et al. (2020) Outcomes and safety of concomitant topiramate or metformin for antipsychotics-induced obesity: A randomized-controlled trial. Ann Gen Psychiatry19: 68.
41.
WangHDwyer-LindgrenLLofgrenKT, et al. (2012) Age-specific and sex-specific mortality in 187 countries, 1970–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet380: 2071–2094.
42.
WangYHuangXFanH, et al. (2021) High-dose betahistine improves cognitive function in patients with schizophrenia: A randomized double-blind placebo-controlled trial. Front Psychiatry12: 762656.
43.
WuR-RZhaoJ-PJinH, et al. (2008) Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: A randomized controlled trial. JAMA299: 185–193.
44.
ZhangLDaiXLiY, et al. (2023) Prevalence and factors associated of metabolic syndrome in first-treatment drug-naïve schizophrenia patients: A large-scale cross-sectional study. Early Interv Psychiatry19: e13565.
45.
ZhengWLiX-BTangY-L, et al. (2015) Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: Meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol35: 499–509.
46.
ZhengWXiangY-TXiangY-Q, et al. (2016) Efficacy and safety of adjunctive topiramate for schizophrenia: A meta-analysis of randomized controlled trials. Acta Psychiatr Scand134: 385–398.
